Skip to the main content

Professional paper

EFFECT OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS ON THE VALUES OF APOLIPOPROTEIN A-1 AND ACUTE PHASE REACTANTS IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS

Husni Ismaili
Suada Mulić-Bačić
Necmedin Karemani
Nikola Orovčanec


Full text: croatian pdf 117 Kb

downloads: 305

cite


Abstract

In this observational study we examined the impact of disease-modifying antirheumatic drugs (DMARDS) on the
disease activity as well as the values of acute phase reactants and the apolipoprotein A1 (Apo A1) in patients with active
rheumatoid arthritis (RA). Eighty patients with active RA and newly discovered RA patients who meet the American
Rheumatology Association (ARA) 1987 revised criteria were treated with disease modifying anti-rheumatic drugs –
DMARDs according to the standard protocol of everyday clinical practice. At 6 and 12 months of treatment the patients
achieved a signifi cant decrease in the disease activity score 28 (DAS28), C-reactive protein (CRP), and erythrocyte
sedimentation rate (ESR) values. On the other hand, the levels of Apo A-1, which were low at baseline, were signifi -
cantly higher. In conclusion, the use of DMARDs in patients with RA reduced disease activity and infl ammation, but
also had a benefi cial eff ect in increasing the levels of atheroprotective Apo A-1 lipoprotein, which can reduce CV risks
in these patients.

Keywords

Arthritis, rheumatoid – drug therapy; Antirheumatic agents – pharmacology, therapeutic use; Apolipoprotein A-1 – blood; Blood sedimentation; C-reactive protein – analysis; Severity of illness index; Atherosclerosis – metabolism, prevention and control

Hrčak ID:

182818

URI

https://hrcak.srce.hr/182818

Publication date:

28.12.2016.

Article data in other languages: croatian

Visits: 1.304 *